fasciotens®Pediatric
fasciotens®Pediatric is used to treat congenital and acquired abdominal wall defects in newborns and infants. In the process, fasciotens®Pediatric applies a standardised and quantifiable traction to the abdominal wall that can be reproduced at any time by the entire medical staff. The abdominal wall is stretched via a ventrally directed traction, the abdominal cavity is enlarged and thus space is created for the organs.
fasciotens®Cradle enables an improved repositioning option for pressure ulcer prophylaxis during therapy.
The problem
- .Abdominal wall defects of different genesis
- .Risk of intra-abdominal compartment syndrome due to primary closure
- .No standardised therapy procedure
- .Applied force currently not quantifiable and uniformly reproducible
- .Acceptance of abdominal wall hernias and follow-up operations
- .Patient positioning very limited
The solution: fasciotens®Pediatric
- .Enlarges the abdominal cavity by stretching the abdominal wall
- .Standardises and quantifies the traction on the abdominal wall
- .Allows reproduction of traction by the treatment team at any time
- .Facilitates direct fascial closure
- .Improves repositioning under constant directional traction
What our customers say:

“Congenital malformations of the abdominal wall and rare acquired abdominal compartment syndromes in early childhood require special therapy of abdominal wall stretching. Various treatment methods have been developed for this purpose. However, these methods do not allow an objectifiable and controlled traction on the abdominal wall.
fasciotens®Pediatric is a method that allows a controlled traction to be applied to the abdominal wall. First results of the application of fasciotens®Pediatric for abdominal wall malformations in newborns are promising.
Currently, a Germany-wide application study is being conducted, for which further participating institutions are invited.”

“Not only is the use of fasciotens®Pediatric in pediatric surgery a promising tool for abdominal wall closure of complex congenital abdominal wall defects – more importantly, it has just been instrumental in decisively influencing the outcome of a little girl in the context of an individual healing trial.
After multiple abdominal compartment syndromes due to metastatic neuroblastoma with massive hepatomegaly, targeted pressure relief of the abdominal organs was life-decisive for the 3-month-old child: this made it possible to continue chemotherapy continuously despite persistent expansion of the metastatic liver. After weeks in the open abdomen with fasciotens, “tumor-free” was then celebrated at Christmas! This is only possible through innovative concepts, university flexibility and close cooperation with the industrial partners of fasciotens.”
Are you interested in fasciotens®Pediatric?
Then contact us – we look forward to the dialogue with you!
Have you already used fasciotens®Pediatric?
Do you have feedback for us?